Holen Sie sich die Stockscreener-App
22.09
0.32%
-0.07
Schlusskurs vom Vortag:
$22.16
Offen:
$21.88
24-Stunden-Volumen:
562.12K
Relative Volume:
0.59
Marktkapitalisierung:
$1.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-221.04M
KGV:
-5.9473
EPS:
-3.7143
Netto-Cashflow:
$-178.65M
1W Leistung:
+1.80%
1M Leistung:
+25.87%
6M Leistung:
+35.52%
1J Leistung:
+219.68%
1-Tages-Spanne:
$21.77
$22.30
1-Wochen-Bereich:
$21.34
$22.79
52-Wochen-Spanne:
$5.68
$23.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
22.09 | 1.38B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results - geneonline.com
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - simplywall.st
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com Australia
Cullinan Therapeutics (CGEM) to Present Phase 3 REZILIENT3 Trial - GuruFocus
Taiho, Cullinan trial results selected for lung cancer conference - Investing.com
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer - marketscreener.com
Cullinan's lung cancer trial met its main goal; results are set for presentation in September - Stock Titan
Cullinan Oncology stock hits 52-week high at 21.55 USD By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Morgan Stanley Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 1-Year HighShould You Buy? - MarketBeat
UBS Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $27 - Moomoo
UBS raises Cullinan Oncology stock price target to $27 on trial data - Investing.com
HC Wainwright Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $30 - GuruFocus
Cullinan Therapeutics (CGEM) Advances in Phase 3 Trial, Shares Near 2-Year High Amid Mixed Signals - GuruFocus
Assenagon Asset Management S.A. Sells 77,023 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 30,000 Shares - MarketBeat
Cullinan Therapeutics (CGEM) investor group discloses 6,491,123-share position - Stock Titan
Cullinan Therapeutics (CGEM): T. Rowe Price reports 6.2% ownership stake - Stock Titan
CGEM (CGEM) insider to sell 30,000 shares after stock option exercise - Stock Titan
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Op - Benzinga
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - MarketBeat
CGEM Maintains Outperform Rating -- Price Target Raised to $42.0 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00 - MarketBeat
Cullinan Therapeutics (CGEM) Shares Rise 6% Premarket on Positiv - GuruFocus
New Taiho, Cullinan data heats up lung cancer drug battle - Yahoo Finance
Show Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next - RTTNews
Cullinan rises on trial win for lung cancer drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan: REZILIENT3 Phase 3 Interim Shows Improved PFS for Zipalertinib + Chemo - TradingView
Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company - MarketBeat
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - BioSpace
Zipalertinib trial meets primary endpoint in lung cancer study - Investing.com Nigeria
Zipalertinib trial meets primary endpoint in lung cancer study By Investing.com - Investing.com Australia
HC Wainwright Issues Pessimistic Outlook for CGEM Earnings - MarketBeat
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com - Investing.com UK
Cullinan says zipalertinib plus chemotherapy meets PFS endpoint in Phase 3 REZILIENT3 lung cancer trial - Bitget
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week HighStill a Buy? - MarketBeat
Possible Bearish Signals With Cullinan Therapeutics Insiders Disposing Stock - Moomoo
Cullinan Oncology stock hits 52-week high at 19.43 USD - Investing.com
Cullinan Therapeutics (CGEM) Wins FDA Backing For CLN 049, Is The Upside Already Priced In? - Sahm
Dimensional Fund Advisors LP Has $12.87 Million Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results - MarketBeat
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cullinan Therapeutics Inc-Aktie (CGEM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
Aug 13 '26 |
Sale |
20.26 |
30,000 |
607,800 |
162,844 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):